Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
John Tyhonas(Ondine Biopharma (United States)), Stephen W. Kaldor(Ondine Biopharma (United States)), Aleksandra Franovic(Ondine Biopharma (United States)), Michelle Salazar Pérez(Ondine Biopharma (United States)), Robert S. Kania(RG Biopharma (United States)), Chun Li(University of Southern California), Adithi Mohan(Ondine Biopharma (United States)), Eric S. Martin(Dana-Farber Cancer Institute), Noel Timple(Ondine Biopharma (United States)), Kathryn B. Grandinetti(Ondine Biopharma (United States)), Nichol Miller(Pfizer (United States)), Elisabeth Gardiner(Saudi Aramco (United States)), Lee D. Arnold(ArmaGen (United States)), Sean Uryu(Pfizer (United States)), Liliana Soroceanu(California Pacific Medical Center), Scott Womble(Ondine Biopharma (United States)), Matthew Lardy(Ondine Biopharma (United States)), Jason M. Cox, Eric A. Murphy(University of California San Diego), Toufike Kanouni(Ondine Biopharma (United States))
Cited by 18
Related Papers
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
|Cell|2012|2k
Telomere dysfunction induces metabolic and mitochondrial compromise
|Nature|2011|1.3k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Genome-wide association identifies multiple ulcerative colitis susceptibility loci
|Nature Genetics|2010|680